Search
for
Sort by
Research 31–60 of 48
- Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance
- YAP/TAZ Signalling Controls Epidermal Keratinocyte Fate
- Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems
- Low-Molecular-Weight Synthetic Antioxidants: Classification, Pharmacological Profile, Effectiveness and Trends
- Therapeutic potential of hair follicle-derived stem cell intranasal transplantation in a rat model of ischemic stroke
- Knowledge Mapping of Drug Repositioning’s Theme and Development
- Overexpression of hypoxia-inducible factor-1α in hidradenitis suppurativa: the link between deviated immunity and metabolism
- Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
- Recent Insights in Multi‐Target Drugs in Pharmacology and Medicinal Chemistry
- Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases
- Screening of dermatology drugs for aberrant use‐patterns: An application of epidemiologic estimates and measures of inequality in drug use
- Niche-dependent immunometabolic regulation of tissue repair and regeneration
- Transcriptome-guided development of a fibrosis-reversal compound reduces skin scarring and allows regeneration via mitochondrial uncoupling
- Alopecia Associated to the Use of Disease-Modifying Therapies for Multiple Sclerosis: A Scoping Review Protocol
- Development of Ethosomes for the Topical Treatment of Androgenic Alopecia: Ethanol Effect on Dutasteride Targeting to the Hair Follicles
- BIO-ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF FINASTERIDE, TADALAFIL, AND ITS APPLICATION TO PHARMACOKINETIC STUDIES IN RAT PLASMA BY USING LC-MS/MS
- Drug-Induced Hair Loss: Analysis of the Food and Drug Administration’s Adverse Events Reporting System Database
- Application of the waiting time distribution in a nationwide screening of real‐world dermatology drug utilization for aberrant use patterns
- Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis
- 1495 Dimethyl fumarate ameliorates delayed wound healing due to IL-36Ra deficiency through inhibition of NET formation and oxidative stress
- Treating Psoriasis: What Is New About Fumaric Acid Esters?
- Editors' Picks
- “Nail loss after teriflunomide treatment: A new potential adverse event”
- BH25 Alopecia in a patient undergoing multiple treatments for multiple sclerosis: a rare presentation and case review
- Dermatological drugs, topical agents, and cosmetics
- Clinical Snippets
- The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
- Where it all went right
- Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
- Skin Penetration and Permeation Properties of Transcutol® in Complex Formulations